Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 8;9(5):1390.
doi: 10.3390/jcm9051390.

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?

Philipp E Hartrampf  1 , Marieke Heinrich  1 , Anna Katharina Seitz  2 , Joachim Brumberg  1 , Ioannis Sokolakis  3 , Charis Kalogirou  2 , Andreas Schirbel  1 , Hubert Kübler  2 , Andreas K Buck  1 , Constantin Lapa  1   4 , Markus Krebs  2   5
Affiliations

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?

Philipp E Hartrampf et al. J Clin Med. .

Abstract

(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: 68Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland-Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.

Keywords: Prostate-specific membrane antigen (PSMA); agreement; biomarker; comparability; metabolic tumour volume (MTV); software; total lesion PSMA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Statistical agreement of PSMA-TV and TL-PSMA determined by Syngo.via and FIJI at baseline and follow-up. (a,b) PSMA-TV for each patient at baseline (a) and follow-up (b)—determined by Syngo.via and FIJI. (c,d) TL-PSMA at baseline (c) and follow-up (d) determined by both software algorithms. (e–h) Bland–Altman diagrams for illustration and assessment of statistical comparability for each patient. Single outliers with a significant divergence between values determined by Syngo.via and FIJI were marked in red—all others were depicted within a range of 1.96 × standard deviation (SD). PSMA: prostate-specific membrane antigen; PSMA-TV: PSMA tumour volume; TL-PSMA: total lesion PSMA; ns: not significant.
See this image and copyright information in PMC

References

    1. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., van Glabbeke M., van Oosterom A.T., Christian M.C., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000;92:205–216. doi: 10.1093/jnci/92.3.205. - DOI - PubMed
    1. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009;50:122S. doi: 10.2967/jnumed.108.057307. - DOI - PMC - PubMed
    1. Chung H.H., Kim J.W., Han K.H., Eo J.S., Kang K.W., Park N.-H., Song Y.-S., Chung J.-K., Kang S.-B. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol. Oncol. 2011;120:270–274. doi: 10.1016/j.ygyno.2010.11.002. - DOI - PubMed
    1. Dibble E.H., Alvarez A.C.L., Truong M.-T., Mercier G., Cook E.F., Subramaniam R.M. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging. J. Nucl. Med. 2012;53:709–715. doi: 10.2967/jnumed.111.099531. - DOI - PubMed
    1. Lim R., Eaton A., Lee N.Y., Setton J., Ohri N., Rao S., Wong R., Fury M., Schoder H. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J. Nucl. Med. 2012;53:1506–1513. doi: 10.2967/jnumed.111.101402. - DOI - PubMed